Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Plast Reconstr Surg. 2012 Jan;129(1):53–66. doi: 10.1097/PRS.0b013e3182361ff5

Figure 3.

Figure 3

Figure 3

(A) Human VEGF immunohistochemistry in a calvarial defect (brown color) with control shRNA or Noggin shRNA hASCs on a HA coated PLGA scaffold with or without BMP-2 (200ng/ml). (B) VEGFA expression by immunofluorsence (red color) in the region of the calvarial defect treated either with control shRNA treated or Noggin shRNA treated hASCs.